CNS’ Chief Product Strategist, Ruthi Aladjem Ph.D will lead a panel exploring the future of potential of neurotech for mental & cognitive health.

HERZLIYA, Israel – January 16, 2024 – Corundum Neuroscience, the neuroscience venture builder and fund, today announced its participation at the North American Neuromodulation Society (NANS) Annual Meeting, taking place in Las Vegas from January 18-21, 2024. 

During the event, Corundum Neuroscience will partake in a panel discussion at the forum entitled “I3 – Invention, Investment, and Invigoration – Moving Neuromodulation Forward.” JoJo Platt, US Partnerships Lead for Corundum Neuroscience will moderate a panel which will explore key themes in neuromodulation innovation and the investment opportunities on the horizon. Panelists include Josh Schulman, PhD, Chief Scientist at Corundum Neuroscience, Juan-Pablo Mas, Partner at Action Potential Venture Capital, and Ariane Tom, PhD, Founder & Managing Partner for Kaleida Capital. 

“While the broader life sciences sector might have cooled post-Covid, there have been many bright spots in the last year within the neuroscience sector – in both pharma and  neuromodulation,” said Schulman. “I look forward to discussing the opportunities for advancing neuromodulation technologies with my industry colleagues at NANS.”

“NANS has been at the forefront of the neuromodulation community for 30 years now,” noted Platt. “As the industry continues to expand and include therapies beyond pain and other traditional neuromodulation targets, it has retained its focus on supporting the commercialization of novel devices to address critical unmet needs. The investments planned and made in this sector are important components of the ecosystem and we’re proud to be highlighting the latest news and trends.”

Given the extensive development cycles required to bring new neuroscience technologies to market, Corundum Neuroscience takes a long-term view on neuroscience investments. Bringing this important perspective to NANS, the team will pay keen attention to solutions presented at this year’s meeting, particularly focusing on solutions enabled by technological advancements in AI and human-machine interfaces as well as research that demonstrates the potential to translate research to commercial opportunities. 

Corundum Neuroscience brings deep domain expertise to investments in the neuromodulation space, given past investments with companies including GrayMatters Health, developer of FDA-cleared digital self-neuromodulation therapies for mental disorders and NYX, a neurotechnology company currently developing a wearable headset for monitoring and modulating stimulating brain activity.

This year’s event will be the 30th anniversary of the annual meeting for NANS, adding new programming, including Advanced Practice Provider programming, a patient-focused plenary session, and topical sessions exploring applications of artificial intelligence in neuromodulation technologies, as well as debates applicability of these technologies on cancer pain, back pain and essential tremors. The event will provide a platform for medical education, scientific exchange, and networking opportunities within the field of neuromodulation. 


About Corundum Neuroscience 

Corundum Neuroscience is a venture builder and fund advancing transformative neuroscience solutions from lab-to-life. Formerly known as Joy Ventures, the company combines deep domain expertise with a track record of venture-building success to accelerate neuroscience solutions across the entire innovation lifecycle. Headquartered in Herzliya, Israel, Corundum Neuroscience launched in September 2023.

 Our CEO, Liron Nunez Weissman explores the link between sleep and brain function and how it promises advancements in treatments and outcomes across health and disease areas.

Discover how smell impacts hormones, cognition, social connections, and the potential of digitizing smell.

Delve into Dr. Davidson’s groundbreaking research exploring meditation’s impact on the brain.

The company gained clearance to market its flagship product, Prism for PTSD, the first non-invasive, self-neuromodulation adjunct digital therapy for post-traumatic stress disorder (PTSD).

Tech12 reports on CNS portfolio company, NYX’s neurotech solution for better sleep. Article in Hebrew.

The article delves into the groundbreaking research of Prof. Talma Handler and Prof. Asya Rolls who are studying how the brain can influence immune responses.

CNS portfolio company, GrayMatters Health, developer of digital self-neuromodulation therapeutics for mental disorders, announced that it has been named as a Falling Walls Venture Winner.